Stay updated with breaking news from Nasdaq Ocup. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HC Wainwright reaffirmed their buy rating on shares of Ocuphire Pharma (NASDAQ:OCUP – Get Rating) in a report released on Friday, Benzinga reports. HC Wainwright currently has a $20.00 price target on the stock. HC Wainwright also issued estimates for Ocuphire Pharma’s Q1 2023 earnings at ($0.24) EPS, Q2 2023 earnings at ($0.27) EPS, Q3 […]
NDA Submission for Nyxol for RM and Initiation of VEGA-2 on Track for Q4 2022 Topline Data from ZETA-1 Phase 2b Trial of Oral APX3330 Expected in Early...
FARMINGTON HILLS, Mich., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company...
Virtual Webinar to Take Place Friday, October 14th @ 11 AM ET Topline Results from ZETA-1 Phase 2b Trial of APX3330 Expected Later in 4Q 2022 FARMINGTON...
FARMINGTON HILLS, Mich., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company...